Table 1.

Baseline demographics and disease characteristics

CategoryParameterN = 120
GenderMale62 (51.7%)
Female58 (48.3%)
Age (years)Median64.0
Range29–81
<6561 (50.8%)
≥6559 (49.2%)
RaceWhite105 (87.5%)
Black7 (5.8%)
Asian3 (2.5%)
Latino3 (2.5%)
Other2 (1.7%)
Baseline ECOG score041 (34.2%)
152 (43.3%)
226 (21.7%)
31 (0.8%)
Lymphoma diagnosis by CPRGPTCL, NOS77 (64.2%)
AITL22 (18.3%)
ALCL, ALK-negative13 (10.8%)
ALCL, ALK-positive2 (1.7%)
Enteropathy-associated T-cell lymphoma2 (1.7%)
Extranodal NK/T-cell lymphoma, nasal type2 (1.7%)
Hepatosplenic T-cell lymphoma2 (1.7%)
StageI5 (4.2)
II11 (9.2%)
III42 (35.0%)
IV60 (50.0%)
Unknown2 (1.7%)
Prior systemic therapiesMedian (range)2.0 (1.0–8.0)
≥3 prior therapies44 (36.7%)
Prior CHOP or CHOP-like regimen116 (96.7%)
Platinum-containing regimens38 (31.7%)
Other multiagent regimens44 (36.7%)
Prior pralatrexate10 (8.3%)
Corticosteroids4 (3.3%)
Other single-agent regimens20 (16.7%)
Prior stem cell transplant25 (20.8%)